CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study

In patients taking tamoxifen, the genotype causes different exposure of active metabolite endoxifen. The objective of this randomized, open-label, multicenter, phase II study was to prospectively evaluate whether genotype-guided tamoxifen dosing in patients with hormone receptor-positive metastatic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2020-02, Vol.38 (6), p.558-566
Hauptverfasser:	Tamura, Kenji, Imamura, Chiyo K, Takano, Toshimi, Saji, Shigehira, Yamanaka, Takeharu, Yonemori, Kan, Takahashi, Masato, Tsurutani, Junji, Nishimura, Reiki, Sato, Kazuhiko, Kitani, Akira, Ueno, Naoto T, Mushiroda, Taisei, Kubo, Michiaki, Fujiwara, Yasuhiro, Tanigawara, Yusuke
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents, Hormonal - administration & dosage Antineoplastic Agents, Hormonal - metabolism Antineoplastic Agents, Hormonal - pharmacokinetics Breast Neoplasms - drug therapy Breast Neoplasms - genetics Cytochrome P-450 CYP2D6 - genetics Female Genotype Humans Inactivation, Metabolic - genetics Japan Middle Aged ORIGINAL REPORTS Precision Medicine - methods Progression-Free Survival Tamoxifen - administration & dosage Tamoxifen - metabolism Tamoxifen - pharmacokinetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!